Vitamin D Dose Optimization: Why 4000 IU Is Not the Right Answer for Everyone

The internet has settled on a default answer for vitamin D. Take 5000 IU per day. Maybe 4000 IU. Post-Bulletproof podcast, post-Peter Attia, post-Rhonda Patrick — this has become almost the standard biohacker recommendation.

It is oversimplified in ways that matter. Individual response to a given vitamin D dose varies by roughly three to four fold. The largest randomized trial ever conducted in vitamin D supplementation — VITAL, with almost 26,000 participants — did not find the benefits on cancer and cardiovascular events that observational data had predicted. And the target blood level itself is contested, with the Endocrine Society, the Institute of Medicine, and the functional medicine community all publishing different numbers.

This piece walks through why dosing without testing is a coin flip, what the RCT evidence actually shows, and how to build a personal vitamin D protocol that has some chance of doing what you want it to do.

What vitamin D actually is

Vitamin D is a misnomer — it is a secosteroid hormone precursor. Skin synthesizes cholecalciferol (D3) from 7-dehydrocholesterol under UVB. That D3 is hydroxylated in the liver to 25-hydroxyvitamin D (the storage form, the one measured on blood tests) and again in the kidney to 1,25-dihydroxyvitamin D (the active hormone).

The active hormone binds vitamin D receptors expressed in most tissues — bone, gut, kidney, immune cells, and many others. That is why deficiency effects are systemic rather than organ-specific, and why deficiency has correlated with many conditions in observational studies. That correlation pattern has driven a lot of enthusiasm and a lot of overreach.

Why individual response varies so much

Give ten people the same 5000 IU per day vitamin D3 supplement for three months, and their resulting 25-hydroxyvitamin D blood levels will span a three- to four-fold range. The reasons include:

• Body mass and adiposity. Vitamin D is fat-soluble and sequesters in adipose tissue. Higher BMI reduces the serum response to any given oral dose. A person at BMI 35 may need two to three times the dose to reach the same serum level as a person at BMI 22.
• Baseline 25-hydroxyvitamin D. A person starting at 15 ng/mL will rise faster from a fixed dose than a person starting at 35 ng/mL. Serum response is not linear across the whole range.
• Gut absorption. Vitamin D is fat-soluble and requires bile acids for absorption. Cholestatic liver disease, cystic fibrosis, celiac disease, and gastric bypass all reduce absorption.
• Skin pigmentation and sun exposure. Higher melanin content reduces UVB-driven synthesis. A person with darker skin at high latitude synthesizes less endogenous vitamin D, so oral dose contributes a larger fraction of the total.
• VDR polymorphisms. Common variants in the VDR gene affect receptor sensitivity. This is more about how much biological effect a given serum level produces than about serum level itself.
• Season, latitude, and time spent outside. A person who runs at noon in Miami will not need the same supplemental dose as a person who works indoors in Seattle.

The practical implication is that any fixed-dose recommendation — 2000 IU, 4000 IU, 5000 IU — will overdose some people and underdose others. The only way around this is to measure.

The blood test

25-hydroxyvitamin D is the standard test. It is inexpensive, widely available, covered by most insurance when medically indicated, and easily orderable through direct-to-consumer testing services. It measures your storage form, which is the right marker for status.

What you should not use: 1,25-dihydroxyvitamin D. That is the active hormone. It is tightly regulated by parathyroid hormone and calcium and does not reflect status. Some functional medicine practitioners order it inappropriately; it does not answer the supplementation question.

The target range — and the disagreement

There is no consensus on the optimal 25-hydroxyvitamin D level. The three main positions are:

• Institute of Medicine (2011). Sufficiency at 20 ng/mL (50 nmol/L). This is the level at which the vast majority of the population avoids rickets and osteomalacia. The RDA (600 to 800 IU) is set to bring the population to this level.
• Endocrine Society (2011). Sufficiency at 30 ng/mL (75 nmol/L). Insufficiency between 21 and 29. Deficiency below 20.
• Functional and integrative medicine consensus (informal). Target range of 40 to 60 ng/mL, sometimes 50 to 80. Based on observational associations between higher levels and various endpoints.

The functional medicine target is aspirational rather than trial-supported. It is not obviously wrong — some observational data associate levels in the 40 to 60 range with better outcomes — but the causal chain is not established, and it is possible that elevated 25-hydroxyvitamin D is a marker for something else (more outdoor time, better overall health, more affluent lifestyle) rather than a cause of good outcomes.

A reasonable working target for a healthy adult is 30 to 50 ng/mL. This band covers the Endocrine Society threshold, sits well below any toxicity concern, and has enough headroom that mild seasonal fluctuation does not push you into deficiency.

The dose-response relationship

The rough rule of thumb is that 1000 IU per day of oral vitamin D3 raises serum 25-hydroxyvitamin D by roughly 10 ng/mL over eight to twelve weeks in an average adult with average absorption. This is a very rough rule and hides a wide variance.

Concrete example. A 70 kg adult starting at 20 ng/mL and aiming for 40 might reasonably need 2000 IU/day. Same weight starting at 10 ng/mL might need 3000 to 4000 IU. A 90 kg BMI 32 person might need 5000 to 6000. A person already at 35 might not need any supplement.

The right way to run the math is to test, dose, retest at three months, and adjust. The wrong way is to pick a number off a podcast and hope.

The trial evidence

The observational evidence for vitamin D benefits is enormous. The randomized evidence is much more mixed.

VITAL trial (Manson 2019). The largest supplementation RCT ever conducted. 25,871 participants (men over 50 and women over 55) received 2000 IU vitamin D3 per day (with or without omega-3) versus placebo for a median 5.3 years. Primary endpoints: invasive cancer, major cardiovascular events. Result: no significant reduction in either endpoint overall. Some subgroup signals — particularly in participants with lower baseline BMI and possibly lower baseline vitamin D — hinted at benefit, but the trial as designed did not support the strong observational predictions.

Two caveats on VITAL. Baseline 25-hydroxyvitamin D was already around 30 ng/mL — not deficient. And the placebo arm was allowed up to 800 IU on their own, blurring the signal further.

D-Health trial (Neale 2022). 21,315 Australians, 60,000 IU monthly, five years. Also negative on cancer mortality. Similar baseline-repletion issue.

Bone fractures. Mixed. Some meta-analyses show fracture reduction with vitamin D plus calcium co-supplementation, particularly in institutionalized elderly. Vitamin D alone without adequate calcium and without vitamin K2 has weaker effects. Adequate protein intake matters more than most vitamin D trials capture.

Falls in older adults. Modest reduction with vitamin D repletion in deficient older adults. Not a striking effect.

Depression. Mixed. Some effect in seasonal depression and in deficient patients. Not established in general depression.

Respiratory infection. Martineau 2017, a meta-analysis of 25 RCTs, found modest reduction in acute respiratory infection with daily or weekly vitamin D, largest in deficient patients. Daily dosing outperformed bolus dosing.

COVID-19. Mostly negative RCT signals despite strong observational associations. The observational pattern likely reflected confounding.

The honest read across the trial literature: vitamin D correction from deficiency probably matters. Vitamin D supplementation in already-repleted populations does very little on the endpoints trials have measured.

The K2 co-factor question

Vitamin K2 is the fat-soluble vitamin implicated in directing dietary calcium away from arterial deposition and toward bone matrix. There is a mechanistic argument that supplementing high-dose vitamin D without adequate K2 could theoretically increase calcification of arteries and soft tissue, particularly in people with high calcium intake.

The clinical evidence is weaker than the mechanistic argument. Small trials show improved bone density and reduced fracture risk with K2 (MK-7 or MK-4). No large trial has confirmed that D toxicity or coronary calcification is prevented by co-supplementing K2 in humans.

Defensible middle: above 4000 IU D3 per day, add 100 to 200 mcg of K2 (MK-7). At 1000 to 2000 IU with leafy greens in the diet, K2 is optional.

Toxicity — what to actually worry about

Vitamin D toxicity is rare at the doses commonly used in retail supplements. Chronic doses above 10,000 IU per day have produced hypercalcemia in some case reports; single doses in the hundreds of thousands of IU (usually from labeling errors or contaminated products) have caused acute toxicity.

At doses below 4000 IU per day, chronic toxicity is essentially unreported in adults with normal kidney function. Between 4000 and 10,000 IU per day, monitoring becomes wise. Above 10,000 IU per day, monitoring is mandatory.

The label warning about a 50,000 IU capsule product is worth naming.

Vyvata's vitamin D selection

The practical protocol

1. Test 25-hydroxyvitamin D. Order through your primary care doctor or a direct-to-consumer service. Cost is typically 30 to 60 dollars uninsured.
2. Interpret the result. Below 20 ng/mL is deficient. 20 to 30 is insufficient by Endocrine Society thresholds. 30 to 50 is a reasonable working target. Above 60 is not obviously beneficial and starts approaching the range where the K2 conversation matters.
3. Choose a starting dose based on baseline. Below 20, start at 4000 to 5000 IU per day for repletion. 20 to 30, start at 2000 IU. Above 30, 1000 IU maintenance or none if you get regular sun exposure.
4. Take with a fat-containing meal. Vitamin D3 is fat-soluble. Dry capsules taken on an empty stomach absorb poorly.
5. Retest at 12 weeks. This is where most self-directed supplementation goes wrong. Without retesting you do not know whether your response was on the low or high end of the population range.
6. Adjust based on the retest. Overshot 50 ng/mL, drop the dose. Still below 30, increase.
7. Consider K2 at higher doses. Adding 100 to 200 mcg of MK-7 form K2 to doses above 4000 IU is defensible cheap insurance.

Why supplement scores in this category cluster Provisional

Vitamin D3 products score Provisional for the same industry-wide reasons other supplements do — inconsistent heavy-metal testing, unverified IU-content against label (potency drift is a real vitamin D problem), and undisclosed cholecalciferol source. Until a scoring upgrade lands, buying from brands that submit to independent testing (Pure Encapsulations, Thorne, Nordic Naturals) is the practical hedge.

The honest summary

Vitamin D is not a miracle. It is a fat-soluble hormone precursor, correction of deficiency is genuinely important, and modest supplementation in the 1000 to 2000 IU range is a reasonable default for most adults in most climates. Higher doses may be justified but require testing, not guessing. The RDA is set for population-level deficiency prevention, not personal optimization, but the flip side is that the optimization case has thinner trial support than the biohacker consensus admits.

Test. Dose. Retest at three months. Adjust. That is the entire protocol. Anyone selling you a fixed dose without measurement is not doing you a favor.